Visionary Venture Fund

Visionary Ventures Fund is a specialized venture capital firm headquartered in Aliso Viejo, California, exclusively dedicated to investing in the future of ophthalmology. The fund's mission is to identify and support groundbreaking innovations that address unmet needs in eye care, ranging from novel therapeutics and diagnostics to advanced medical devices and digital health solutions. With a deep understanding of the ophthalmic market, the firm leverages its partners' extensive clinical and industry expertise to provide strategic guidance and capital to promising startups.

The fund typically invests across various early-stage rounds, including Seed, Series A, and Series B. While specific check sizes can vary based on the stage and capital requirements of the company, Visionary Ventures Fund generally writes initial checks ranging from approximately $500,000 to $5,000,000. They have demonstrated a capacity to lead or significantly participate in substantial funding rounds, such as their leadership in a $10 million Series A round for ViaLase, a company developing precision laser technology for glaucoma. Their investment strategy emphasizes long-term partnerships with entrepreneurs who are poised to transform the ophthalmic landscape.

To date, Visionary Ventures Fund has built a focused portfolio of innovative companies, having made at least 12 investments in the sector. Notable companies within their portfolio include Visus Therapeutics, OcuTerra Therapeutics, and EyeCRO, all contributing to advancements in different facets of eye health. Their involvement often extends beyond capital, providing portfolio companies with access to a robust network of key opinion leaders, industry experts, and potential strategic partners within the ophthalmology ecosystem. This hands-on approach underscores their commitment to fostering the growth and success of their portfolio companies, ultimately aiming to bring new solutions to patients worldwide.